about
How are topical opioids used to manage painful cutaneous lesions in palliative care? A critical review.EWMA document: Antimicrobials and non-healing wounds. Evidence, controversies and suggestions.Compression therapy in patients with venous leg ulcers.Management of Patients With Venous Leg Ulcers: Challenges and Current Best Practice.Antimicrobials and Non-Healing Wounds. Evidence, controversies and suggestions-key messages.Malignant fungating wounds: a survey of nurses' clinical practice in Switzerland.Current practice in the management of wound odour: an international survey.Coping with an exulcerated breast carcinoma: an interpretative phenomenological study.Caring for a loved one with a malignant fungating woundEWMA Document: Home Care-Wound Care: Overview, Challenges and PerspectivesWounds with exudate and odourM.O.I.S.T. - a concept for the topical treatment of chronic woundsEvaluation of needs and treatment benefits in outpatient care for leg ulcer patients: a pilot studyComparison of sterile polyacrylate wound dressing with activated carbon cloth and a standard non-adhesive hydrocellular foam dressing with silver: a randomised controlled trial protocolA targeted interprofessional educational intervention to address therapeutic adherence of venous leg ulcer persons (TIEIVLU): study protocol for a randomized controlled trialWound Curriculum for Nurses: Post-registration qualification wound management - european qualification framework level 6Internal consistency and reliability of the Swiss-French translation of the venous leg ulcer self efficacy tool (VeLUSET)The lived experience of recurrence prevention in patients with venous leg ulcers: An interpretative phenomenological studyAntimicrobials and Non-healing Wounds Evidence, controversies and suggestions
P50
Q38115422-0E0606C7-088B-4F70-95E7-EA2E447559E0Q38197186-836301ED-4EAC-428E-B2CD-2743788EB90CQ39017910-DCF02CBE-9A8D-478F-B9A1-F89D8F6178BEQ40705570-9EE2B351-6A77-42F4-A60C-EBEA60A2D257Q41710772-B64436F2-323F-42F8-847D-9B4EF057AD07Q43497422-D69C13A2-D9E6-47FC-BD25-B82E013A5746Q43697726-2B8FE621-4116-434C-8E5D-0C81ACC415E0Q44993679-AAFC8EFD-DDE2-449A-97CC-A68BA105C166Q83575468-3066880F-B1E3-485F-9EAC-F2792EF1E8D9Q85257406-17EFCAAD-05CC-4518-9E1F-DA0DBAD2ABB7Q87007465-D04DB6BA-58CF-499B-959E-6B7BB3F6E6F0Q89509909-3EE647A4-D2FB-473F-B306-F4E9149346CBQ90817251-28329C70-E2EB-4129-87B3-1534FFF2F4C9Q91267135-A166C6B4-402F-457B-8633-F21F730EE9E7Q91617802-09BBF189-E9BB-45E7-A0F5-0CBCD04FDB8BQ91793608-B9A2F758-C3F6-4141-9221-C99FC13BE949Q91823457-2DA0A6C1-87D5-4921-97A1-6B90983CBD62Q92887543-C608583C-F183-4BD2-A535-32A64E138BA9Q95400416-297EB18B-2B53-40EF-B6B2-1A2D868AF788
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sebastian Probst
@ast
Sebastian Probst
@en
Sebastian Probst
@es
Sebastian Probst
@nl
type
label
Sebastian Probst
@ast
Sebastian Probst
@en
Sebastian Probst
@es
Sebastian Probst
@nl
prefLabel
Sebastian Probst
@ast
Sebastian Probst
@en
Sebastian Probst
@es
Sebastian Probst
@nl
P106
P31
P496
0000-0001-9603-1570